Selecta Biosciences is focused on dramatically improving human health through its Synthetic Vaccine Particle (SVP™) platform. This proprietary and entirely new platform for vaccine development enables the induction of antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic application.

Selecta's SVP™ platform is flexible and the company has created targeted Synthetic Vaccine Particles (tSVP™) that elicit vigorous immune responses to a wide array of relevant antigens, including small molecules, peptides, oligosaccharides, and proteins. These particles can target humoral or cellular pathways of the immune system. Examples of applications include cancer, infectious diseases, allergies, and addiction.

The targeted tolerogenic Synthetic Vaccine Particles (t²SVP™) are designed to induce antigen-specific immune tolerance. Examples of applications include autoimmune diseases, allergies, and transplant rejection.

 

 

 

 

By using self assembling and modular synthetic nanoparticle technology, the SVP™ platform uniquely incorporates the essential elements required for an antigen-specific and robust immune modulation.

The first tSVP™ has entered Phase 1 clinical development in 2011. This milestone demonstrates scalability and translation of the tSVP™ platform.